HLS Therapeutics Announces NILEMDOTM is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
